secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001628280-26-028601
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam Q1 net product revs $1.04B (+121%); GAAP EPS $1.51 vs -$0.14; reaffirms FY26 guidance
--------------------------------------------------------------------------------

- Global net product revenues $1,036M, up 121% YoY; total TTR revenues $910M (+153%).
- GAAP net income $206M vs loss $18M; GAAP diluted EPS $1.51; non-GAAP EPS $1.99.
- Reiterates FY26 combined net product revenue guidance of $4.9B-$5.3B.
- AMVUTTRA (vutrisiran) net product revenues $890M; TRITON-CM expanded to ~1,750 patients.
- Initiated Phase 1 obesity trial (ALN-2232) and new collaborations with Viz.ai, AHA, Tenaya, Helix.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000162828026028601/0001628280-26-028601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000162828026028601/alny-20260430.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-028601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer